Autorisation d’accès précoce refusée à la spécialité QALSODY (tofersen) dans l’indication « traitement des adultes atteints de sclérose latérale amyotrophique (SLA) associée à une mutation du gène superoxyde dismutase 1 (SOD1) ».
See also
HAS opinions and decisions
22/10/2024
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
RHaSv92PYSWKCmkE
